Sanofi

SWX:SAN Stock Report

Market Cap: CHF 85.5b

Sanofi Valuation

Is SAN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SAN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: SAN (CHF73.2) is trading below our estimate of future cash flow value (CHF266.88)

Significantly Below Future Cash Flow Value: SAN is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SAN?

Key metric: As SAN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SAN. This is calculated by dividing SAN's market cap by their current earnings.
What is SAN's PE Ratio?
PE Ratio19.1x
Earnings€4.83b
Market Cap€92.34b

Price to Earnings Ratio vs Peers

How does SAN's PE Ratio compare to its peers?

The above table shows the PE ratio for SAN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average40.4x
GALD Galderma Group
81.7x23.93%CHF 39.9b
SDZ Sandoz Group
38.5x16.94%CHF 27.6b
ROP Roche Holding
20.6x8.54%CHF 264.4b
NOVN Novartis
20.9x9.34%CHF 225.6b
SAN Sanofi
19.1x17.76%CHF 92.3b

Price-To-Earnings vs Peers: SAN is good value based on its Price-To-Earnings Ratio (19.1x) compared to the peer average (39.7x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does SAN's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
SAN 19.1xIndustry Avg. 20.8xNo. of Companies9PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SAN is good value based on its Price-To-Earnings Ratio (19.1x) compared to the European Pharmaceuticals industry average (20.7x).

Price to Earnings Ratio vs Fair Ratio

What is SAN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SAN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.1x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SAN's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SAN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 73.20
CHF 89.06
+21.67%
9.20%CHF 103.56CHF 75.82n/a23
Jul ’27CHF 73.20
CHF 89.20
+21.86%
8.73%CHF 103.31CHF 75.64n/a23
Jun ’27CHF 73.20
CHF 88.80
+21.31%
8.73%CHF 102.43CHF 74.99n/a23
May ’27CHF 73.20
CHF 88.95
+21.51%
8.73%CHF 102.60CHF 75.12n/a23
Apr ’27n/a
CHF 88.81
0%
12.33%CHF 103.50CHF 52.68n/a23
Mar ’27n/a
CHF 89.51
0%
9.25%CHF 108.15CHF 72.71n/a23
Feb ’27n/a
CHF 91.68
0%
8.33%CHF 109.09CHF 77.92n/a23
Jan ’27n/a
CHF 97.58
0%
5.92%CHF 110.74CHF 88.40n/a21
Dec ’26n/a
CHF 99.29
0%
6.89%CHF 116.61CHF 88.76n/a22
Nov ’26n/a
CHF 99.11
0%
7.00%CHF 115.76CHF 88.12n/a22
Oct ’26n/a
CHF 101.13
0%
7.69%CHF 116.62CHF 85.97n/a22
Sep ’26n/a
CHF 101.54
0%
8.37%CHF 117.00CHF 84.38n/a22
Aug ’26n/a
CHF 102.71
0%
7.45%CHF 116.34CHF 85.77n/a22
Jul ’26n/a
CHF 106.85
0%
6.57%CHF 118.64CHF 92.48CHF 73.2023
Jun ’26n/a
CHF 109.24
0%
5.47%CHF 118.63CHF 93.41CHF 73.2022
May ’26n/a
CHF 110.14
0%
5.06%CHF 118.83CHF 93.57CHF 73.2021
Apr ’26n/a
CHF 114.05
0%
5.43%CHF 124.40CHF 95.70n/a21
Mar ’26n/a
CHF 109.27
0%
5.68%CHF 117.04CHF 93.63n/a21
Feb ’26n/a
CHF 109.67
0%
6.09%CHF 118.01CHF 94.40n/a22
Jan ’26n/a
CHF 106.43
0%
7.52%CHF 115.03CHF 79.49n/a21
Dec ’25n/a
CHF 106.30
0%
7.40%CHF 117.39CHF 83.85n/a21
Nov ’25n/a
CHF 107.15
0%
7.40%CHF 118.34CHF 84.53n/a21
Oct ’25n/a
CHF 106.86
0%
8.94%CHF 122.50CHF 80.10n/a22
Sep ’25n/a
CHF 103.01
0%
8.52%CHF 117.46CHF 79.87n/a22
Aug ’25n/a
CHF 104.45
0%
8.40%CHF 118.80CHF 80.78n/a23
Jul ’25n/a
CHF 104.81
0%
9.17%CHF 121.21CHF 77.57n/a22
CHF 91.63
Fair Value
20.1% undervalued intrinsic discount
23
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/16 19:36
End of Day Share Price 2026/07/16 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sanofi is covered by 51 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John EadeArgus Research Company
Odile RundquistBaader Helvea Equity Research
null nullBanco de Sabadell. S.A.